Hims & Hers stock outlook: Upward price move faces resistance at $28.53

Traders Union
All News
Stocks
Hims & Hers jumps 8.06% on new deals

Highlights

Hims & Hers Health secured agreements with Eli Lilly to provide Zepbound and Foundayo through its telehealth platform for weight management.
These deals, along with existing Novo Nordisk collaborations, expand the companys direct-to-patient obesity and metabolic prescription portfolio.
Shares of Hims & Hers Health jumped 8.06% intraday to $26, with technicals indicating strong short-term buying, elevated volatility, and a $23.47 to $28.53 trading range.

Weight management access expands as new pharma deals drive platform growth

Hims & Hers Health has confirmed new agreements with Eli Lilly to make FDA-approved Zepbound and Foundayo available through its telehealth platform, expanding its range of weight management treatments and broadening direct-to-patient access, according to Finance Biggo. These collaborations, following similar arrangements with Novo Nordisk, enhance the company's prescription portfolio and position it to capture increasing consumer demand for obesity and metabolic health solutions. This strategic move supports both platform growth and revenue diversification, aligning with increased market interest in digital health channels.

Mixed momentum as intermediate resistance and overbought signals constrain upside

On the technical front, HIMS is holding above its MA-20 but remains capped below the MA-50 and MA-200, signaling a zone of intermediate and long-term resistance. The Ichimoku Kijun at $25.77 acts as immediate support. Momentum readings are split: MACD signals a strong sell, while ADX points to continued buying pressure. Both the RSI and CCI are neutral, but Stochastic RSI is deep in overbought territory, increasing the risk of a near-term correction. Bull/Bear Power shows a positive reading at 0.8, indicating active buyers today, while the Awesome Oscillator is neutral.

Sideways scenario favored as volatility and resistance temper outlook

In the short term, HIMS is likely to consolidate within the $23.47 to $28.53 range based on recent volatility. Upward continuation has a 38% probability, while a downside break is more likely at 62%. A push above resistance could extend recent gains, but a loss of support near $25.77 may prompt further retracement. The most probable scenario is sideways movement within the established corridor as buyers and sellers test these boundaries.

Anton Kharitonov, Traders Union expert, sees Hims & Hers Health benefiting from its latest Eli Lilly agreements, which expand its telehealth drug portfolio and appeal to demand trends in obesity treatment. However, he notes that the stock faces clear technical resistance and mixed momentum signals, with a high chance of sideways price action or a downside break in the near term. He remains cautious despite the positive news backdrop. "Until HIMS can decisively clear $28.53, I see more risk than reward and would avoid aggressive entries here."

Earlier, analysts noted that Hims & Hers faced ongoing downside pressure amid divided technical signals and heightened volatility. The current analysis introduces expanded pharmaceutical partnerships as a potential catalyst but with technical indicators remaining mixed, traders should watch for a sustained move above the MA-50 for confirmation of trend reversal.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.